Clinical Trials Browser

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT03395873 2019-08-21

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

Phase 1 Terminated

7 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03752138 2019-05-06

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Phase 1 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02323607 2019-01-25

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Phase 1 Completed

13 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02412475 2019-01-24

Epigenetic Reprogramming in Relapse AML

Phase 1 Terminated

3 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00791271 2018-11-09

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Phase 1 Terminated

17 enrolled

Dermatologic

Melanoma

NCT02264873 2018-10-15

Phase I, Dose Escalation Study of Decitabine

Phase 1 Completed

3 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01876641 2018-09-19

ML28604

Phase 1 Terminated

18 enrolled

Dermatologic

Melanoma

NCT01352650 2018-07-02

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

Phase 1 Completed

71 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT01798901 2018-03-14

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia

Phase 1 Completed

13 enrolled

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT02141477 2018-02-13

Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 1 Terminated

2 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02093403 2017-12-08

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

25 enrolled

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01241162 2017-05-09

Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma

Phase 1 Completed

19 enrolled

CNSSarcoma

Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial

NCT02564536 2017-05-08

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Juvenile, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Clinical Trials

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

Avapritinib With Decitabine in Patients With SM-AHN

Inqovi Maintenance Therapy in Myeloid Neoplasms

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

FHD-286

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Epigenetic Reprogramming in Relapse/Refractory AML

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

PANDA-T0

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

DERANO

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Epigenetic Reprogramming in Relapse AML

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Phase I, Dose Escalation Study of Decitabine

ML28604

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia

Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)